Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash & Current Investments: 2009-2024

Historic Cash & Current Investments for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to $47.8 million.

  • Lineage Cell Therapeutics' Cash & Current Investments rose 23.77% to $40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $178.5 million, marking a year-over-year increase of 18.74%. This contributed to the annual value of $47.8 million for FY2024, which is 34.69% up from last year.
  • Lineage Cell Therapeutics' Cash & Current Investments amounted to $47.8 million in FY2024, which was up 34.69% from $35.5 million recorded in FY2023.
  • Lineage Cell Therapeutics' Cash & Current Investments' 5-year high stood at $97.1 million during FY2022, with a 5-year trough of $35.5 million in FY2023.
  • For the 3-year period, Lineage Cell Therapeutics' Cash & Current Investments averaged around $60.1 million, with its median value being $47.8 million (2024).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first spiked by 66.46% in 2022, then slumped by 63.46% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Cash & Current Investments (Yearly) stood at $41.6 million in 2020, then spiked by 40.41% to $58.4 million in 2021, then skyrocketed by 66.46% to $97.1 million in 2022, then plummeted by 63.46% to $35.5 million in 2023, then spiked by 34.69% to $47.8 million in 2024.